In the SURPASS-3 study, 1947 T2DM patients with poor glycometabolic control who were treated with metformin, with or without SGLT2 inhibitors, were enrolled, and the efficacy and safety of tirzepatide versus titrated insulin degludec were evaluated. The gene discussed is INS; the disease is type 2 diabetes mellitus.